X

Trial Profile

A Phase III Open-label Extension Study to Evaluate Long-term Safety and Efficacy of PRM-151 in Patients With Idiopathic Pulmonary Fibrosis (IPF)

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 20 May 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Zinpentraxin alfa (Primary)
Indications Idiopathic pulmonary fibrosis
Focus Adverse reactions; Registrational; Therapeutic Use
Acronyms STARSCAPE-OLE
Sponsors Roche

Most Recent Events

17 Mar 2023 This trial has been completed in Poland (End Date: 10 Feb 2023) according to European Clinical Trials Database record.
15 Mar 2023 Status changed from active, no longer recruiting to discontinued.
08 Mar 2023 This trial has been discontinued in Denmark (End Date: 10 Feb 2023), according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com